eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
Eyenovia Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia
Eyenovia, Inc. Announces Adjournment of 2020 Annual Meeting of Stockholders to June 30, 2020  and Change to a Virtual Meeting Format
Upcoming Events
Date Title
Wednesday, August 12, 2020 4:30 PM EDT